Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=27 How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
N/A N=5 Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Primary: Number of LDLR Gene Mutations — 7 gene mutations
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
N/A N=20 Lipoprotein Apheresis in Refractory Angina Study
Refractory Angina · Raised Lipoprotein(a)>50mg/dL or >500mg/L
Primary: Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging — 0.47; -0.16 ratio — p=0.001
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Phase 2 N=23 A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
Hypercholesterolemia
Primary: Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15 — -62.48; -8.77; -48.21; -4.93 percent change — p== 0.0009
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
N/A N=90 PERIODONTAL DISEASE AND HYPERLIPIDEMIA
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Phase 2 N=4 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
Familial Partial Lipodystrophy
Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change
Phase 3 N=62 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Heterozygous Familial Hypercholesterolemia
Primary: Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18 — 0.806; 0.128 Treatments — p=< 0.0001
Phase 2 N=9 A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percentage Change From Day 1 to Day 90 in LDL-C — -12.26 percent change
Phase 2 N=10 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Phase 3 N=58 Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Homozygous Familial Hypercholesterolemia
Primary: Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -16.5 percent change
N/A N=57 The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux
Lipid Metabolism Disorders
Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio
Phase 2 N=15 Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
Hypertriglyceridemia
Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid
Phase 2 N=36 Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
Hypercholesterolemia · Hyperlipoproteinemia Type II
Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants
Phase 2 N=18 Cholic Acid for Hepatic Steatosis in Lipodystrophy
Hepatic Steatosis
Primary: Hepatic Triglyceride (%) — 15.9; 14.8 Fat/Fat+Water (%) — p=0.42
Phase 2 N=286 Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Elevated Lipoprotein(a) · Cardiovascular Disease
Primary: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point — -35; -56; -72; -58 percent change — p=0.0032
Phase 3 N=69 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) — 8.6; -26.9 Percentage of change — p=<0.0001
Phase 2 N=9 Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period — -49.17 Percent Change
N/A N=93 A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
Dyslipidemia · Hypercholesterolemia
Primary: Postprandial Incremental Area Under the Curve From 0-6 Hours (iAUC)[0-6] of Apolipoprotein B-48 (ApoB-48) — 63.4; 41.7 μg/mL x h — p=0.0078
Phase 1 N=49 A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
Hypercholesterolemia · Dyslipidemias · Hyperlipidemias
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-04950615 — 65810; 15900; 8922; 10470 nanogram per milliliter (ng/mL)
Phase 3 N=67 The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — 17.6; -76.5 percent change — p=< 0.0001
N/A N=18 (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
Hypercholesterolemia
Primary: Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P…
Phase 4 N=113 Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
Familial Hypercholesterolemia
Primary: Occurence of Death — 1; 1; 1; 1 participants
Phase 3 N=89 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
N/A N=1,713 Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Type2 Diabetes
Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Phase 4 N=53 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood
Hyperlipidemia
Primary: Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction — -6.50; 5.05; -12.35; 4.64 Percent…
Phase 2 N=120 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Hyperlipidemias
Primary: TG Change (mg/dL ) — -9.2; 14.6; -4.2; -1.3 percentage of change